Which has better earnings and valuation, ACIU or AKTS?

Aktis Oncology has higher revenue and earnings than AC Immune. Aktis Oncology is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AC Immune $4.31M 59.03 -$85.03M -$0.54 N/A Aktis Oncology $6.50M 150.09 -$63.73M -$0.82 N/A

Does the media favor ACIU or AKTS?

In the previous week, Aktis Oncology had 4 more articles in the media than AC Immune. MarketBeat recorded 6 mentions for Aktis Oncology and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.03 beat Aktis Oncology's score of 0.01 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ACIU or CVAC?

AC Immune presently has a consensus price target of $7.50, suggesting a potential upside of 200.00%. Given AC Immune's stronger consensus rating and higher possible upside, equities analysts clearly believe AC Immune is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, ACIU or CVAC?

CureVac has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AC Immune $4.31M 59.03 -$85.03M -$0.54 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Is ACIU or CVAC more profitable?

CureVac has a net margin of 199.92% compared to AC Immune's net margin of -245.32%. CureVac's return on equity of -23.03% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -245.32% -100.17% -28.36% CureVac 199.92% -23.03% -19.09%

Does the media prefer ACIU or CVAC?

In the previous week, AC Immune had 1 more articles in the media than CureVac. MarketBeat recorded 2 mentions for AC Immune and 1 mentions for CureVac. AC Immune's average media sentiment score of 1.03 beat CureVac's score of 0.00 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CureVac 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, SVRA or ACIU?

AC Immune has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A AC Immune $4.31M 59.03 -$85.03M -$0.54 N/A

Is SVRA or ACIU more profitable?

Savara has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Savara's return on equity of -90.28% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% AC Immune -245.32% -100.17% -28.36%

Does the media refer more to SVRA or ACIU?

In the previous week, Savara had 6 more articles in the media than AC Immune. MarketBeat recorded 8 mentions for Savara and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.03 beat Savara's score of 0.16 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral AC Immune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor JANX or ACIU?

In the previous week, Janux Therapeutics had 2 more articles in the media than AC Immune. MarketBeat recorded 4 mentions for Janux Therapeutics and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.03 beat Janux Therapeutics' score of 0.34 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AC Immune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ANL or ACIU?

Adlai Nortye has higher revenue and earnings than AC Immune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 201.19 -$35.53M N/A N/A AC Immune $4.31M 59.03 -$85.03M -$0.54 N/A

Is ANL or ACIU more profitable?

Adlai Nortye has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Adlai Nortye's return on equity of 0.00% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A AC Immune -245.32% -100.17% -28.36%

Does the media favor ANL or ACIU?

In the previous week, Adlai Nortye had 6 more articles in the media than AC Immune. MarketBeat recorded 8 mentions for Adlai Nortye and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.03 beat Adlai Nortye's score of 0.62 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AC Immune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AC Immune (ACIU) Competitors

$2.50 -0.05 (-1.96%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.50 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Compare

ACIU vs. AKTS, CVAC, SVRA, JANX, and ANL

Should you buy AC Immune stock or one of its competitors? AC Immune's main competitors and comparable companies include Aktis Oncology (AKTS), CureVac (CVAC), Savara (SVRA), Janux Therapeutics (JANX), and Adlai Nortye (ANL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AC Immune compare to Aktis Oncology?

AC Immune (NASDAQ:ACIU) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Aktis Oncology has higher revenue and earnings than AC Immune. Aktis Oncology is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	59.03	-$85.03M	-$0.54	N/A
Aktis Oncology	$6.50M	150.09	-$63.73M	-$0.82	N/A

In the previous week, Aktis Oncology had 4 more articles in the media than AC Immune. MarketBeat recorded 6 mentions for Aktis Oncology and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.03 beat Aktis Oncology's score of 0.01 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

51.4% of AC Immune shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Comparatively, 3.3% of Aktis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

AC Immune currently has a consensus target price of $7.50, suggesting a potential upside of 200.00%. Aktis Oncology has a consensus target price of $35.63, suggesting a potential upside of 96.28%. Given AC Immune's higher possible upside, analysts plainly believe AC Immune is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Aktis Oncology has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Aktis Oncology's return on equity of 0.00% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Aktis Oncology	N/A	N/A	N/A

Summary

Aktis Oncology beats AC Immune on 9 of the 15 factors compared between the two stocks.

How does AC Immune compare to CureVac?

AC Immune (NASDAQ:ACIU) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

51.4% of AC Immune shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to AC Immune's net margin of -245.32%. CureVac's return on equity of -23.03% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
CureVac	199.92%	-23.03%	-19.09%

AC Immune has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

AC Immune presently has a consensus price target of $7.50, suggesting a potential upside of 200.00%. Given AC Immune's stronger consensus rating and higher possible upside, equities analysts clearly believe AC Immune is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CureVac has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	59.03	-$85.03M	-$0.54	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

In the previous week, AC Immune had 1 more articles in the media than CureVac. MarketBeat recorded 2 mentions for AC Immune and 1 mentions for CureVac. AC Immune's average media sentiment score of 1.03 beat CureVac's score of 0.00 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CureVac	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AC Immune beats CureVac on 9 of the 17 factors compared between the two stocks.

How does AC Immune compare to Savara?

Savara (NASDAQ:SVRA) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Savara has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Savara's return on equity of -90.28% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
AC Immune	-245.32%	-100.17%	-28.36%

Savara currently has a consensus price target of $10.25, suggesting a potential upside of 108.33%. AC Immune has a consensus price target of $7.50, suggesting a potential upside of 200.00%. Given AC Immune's higher possible upside, analysts plainly believe AC Immune is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Savara had 6 more articles in the media than AC Immune. MarketBeat recorded 8 mentions for Savara and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.03 beat Savara's score of 0.16 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
AC Immune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AC Immune has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
AC Immune	$4.31M	59.03	-$85.03M	-$0.54	N/A

87.9% of Savara shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Savara has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market.

Summary

AC Immune beats Savara on 8 of the 15 factors compared between the two stocks.

How does AC Immune compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Janux Therapeutics had 2 more articles in the media than AC Immune. MarketBeat recorded 4 mentions for Janux Therapeutics and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.03 beat Janux Therapeutics' score of 0.34 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AC Immune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AC Immune has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$24M	46.85	-$113.62M	-$1.64	N/A
AC Immune	$4.31M	59.03	-$85.03M	-$0.54	N/A

Janux Therapeutics presently has a consensus price target of $36.46, indicating a potential upside of 98.27%. AC Immune has a consensus price target of $7.50, indicating a potential upside of 200.00%. Given AC Immune's stronger consensus rating and higher possible upside, analysts clearly believe AC Immune is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Janux Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Janux Therapeutics' return on equity of -11.89% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
AC Immune	-245.32%	-100.17%	-28.36%

Janux Therapeutics has a beta of 2.4, indicating that its share price is 140% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market.

Summary

Janux Therapeutics beats AC Immune on 9 of the 16 factors compared between the two stocks.

How does AC Immune compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Adlai Nortye had 6 more articles in the media than AC Immune. MarketBeat recorded 8 mentions for Adlai Nortye and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.03 beat Adlai Nortye's score of 0.62 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AC Immune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye currently has a consensus target price of $29.50, indicating a potential upside of 88.86%. AC Immune has a consensus target price of $7.50, indicating a potential upside of 200.00%. Given AC Immune's higher probable upside, analysts plainly believe AC Immune is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Adlai Nortye has higher revenue and earnings than AC Immune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	201.19	-$35.53M	N/A	N/A
AC Immune	$4.31M	59.03	-$85.03M	-$0.54	N/A

Adlai Nortye has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

Adlai Nortye has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Adlai Nortye's return on equity of 0.00% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
AC Immune	-245.32%	-100.17%	-28.36%

Summary

Adlai Nortye beats AC Immune on 9 of the 14 factors compared between the two stocks.

Get AC Immune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACIU vs. The Competition

Export

Metric	AC Immune	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$259.52M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.36%
P/E Ratio	-4.63	13.42	274.15	26.16
Price / Sales	59.03	1,237.94	590.34	94.78
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	4.63	17.17	11.21	6.34
Net Income	-$85.03M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-8.09%	-1.33%	-0.90%	-1.41%
1 Month Performance	-7.06%	-8.44%	-4.44%	-3.48%
1 Year Performance	-29.58%	14.02%	6.96%	1.16%

AC Immune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACIU AC Immune	3.0064 of 5 stars	$2.50 -2.0%	$7.50 +200.0%	-28.2%	$259.52M	$4.31M	N/A	106	Positive News
AKTS Aktis Oncology	2.5932 of 5 stars	$19.60 +1.3%	$35.63 +81.8%	N/A	$1.05B	$6.50M	N/A	79	Positive News
CVAC CureVac	0.0744 of 5 stars	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
SVRA Savara	2.2702 of 5 stars	$5.08 +0.1%	$10.00 +97.0%	+43.9%	$1.04B	N/A	N/A	70	News Coverage Analyst Forecast
JANX Janux Therapeutics	2.6137 of 5 stars	$16.92 +2.1%	$36.46 +115.5%	-28.9%	$1.03B	$10M	N/A	113

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACIU) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AC Immune (ACIU) Competitors

ACIU vs. AKTS, CVAC, SVRA, JANX, and ANL

How does AC Immune compare to Aktis Oncology?

Summary

How does AC Immune compare to CureVac?

Summary

How does AC Immune compare to Savara?

Summary

How does AC Immune compare to Janux Therapeutics?

Summary

How does AC Immune compare to Adlai Nortye?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AC Immune (ACIU) Competitors

ACIU vs. AKTS, CVAC, SVRA, JANX, and ANL

How does AC Immune compare to Aktis Oncology?

Which has better earnings and valuation, ACIU or AKTS?

Does the media favor ACIU or AKTS?

Do institutionals and insiders hold more shares of ACIU or AKTS?

Do analysts recommend ACIU or AKTS?

Is ACIU or AKTS more profitable?

Summary

How does AC Immune compare to CureVac?

Do insiders and institutionals hold more shares of ACIU or CVAC?

Is ACIU or CVAC more profitable?

Which has more risk & volatility, ACIU or CVAC?

Do analysts recommend ACIU or CVAC?

Which has preferable valuation and earnings, ACIU or CVAC?

Does the media prefer ACIU or CVAC?

Summary

How does AC Immune compare to Savara?

Is SVRA or ACIU more profitable?

Do analysts recommend SVRA or ACIU?

Does the media refer more to SVRA or ACIU?

Which has preferable earnings and valuation, SVRA or ACIU?

Do institutionals and insiders believe in SVRA or ACIU?

Which has more risk and volatility, SVRA or ACIU?

Summary

How does AC Immune compare to Janux Therapeutics?

Do insiders and institutionals have more ownership in JANX or ACIU?

Does the media favor JANX or ACIU?

Which has higher valuation and earnings, JANX or ACIU?

Do analysts rate JANX or ACIU?

Is JANX or ACIU more profitable?

Which has more risk & volatility, JANX or ACIU?

Summary

How does AC Immune compare to Adlai Nortye?

Do insiders & institutionals have more ownership in ANL or ACIU?

Does the media favor ANL or ACIU?

Do analysts recommend ANL or ACIU?

Which has preferable valuation & earnings, ANL or ACIU?

Which has more risk and volatility, ANL or ACIU?

Is ANL or ACIU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools